A randomized, double-blind, active-controlled crossover study to evaluate the efficacy and safety of fentanyl buccal tablets compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain, followed by a 12-week open-label extension to evaluate the impact of fentanyl buccal tablets on patient outcomes (Protocol #C25608/3056/BP/US),
Role: Investigator,
Cephalon Inc.,
(11/2009 - 11/2010)
Status: Completed
A randomized, double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the treatment of breakthrough cancer pain (INS-05-001),
Role: Investigator,
InSys Therapeutics, Inc.,
(08/2009 - 08/2010)
Status: Completed
A double blind, randomized, placebo controlled, parallel group dose-range exploration study of Sativex® in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy,
Role: Investigator,
G W Pharmaceuticals,
(05/2009 - 05/2010)
Status: Completed
A multicenter, placebo-controlled, double-blind, two-phase crossover study of Nasalfent (fentanyl citrate nasal spray) in the treatment of breakthrough cancer pain (BTCP) in subjects taking regular opioid therapy (CP043/06/FCNS),
Role: Investigator,
Archimedes Development Ltd.,
(01/2009 - 01/2010)
Status: Completed
Reducing pain in people with chronic back pain using dry and moist heat wraps,
Role: Investigator,
Procter & Gamble Company,
(10/2008 - 10/2009)
Status: Completed
An open-label, two-stage, phase II study to explore the titration schedule for transitioning opioid-experienced patients with non-malignant moderate to severe chronic pain from current opioid therapy to the sufentanil transdermal therapeutic system (#EN3270-201),
Role: Investigator,
Endo Pharmaceuticals,
(06/2008 - 06/2009)
Status: Completed
A randomized, double-blind, placebo controlled, crossover study of RWJ-333369 for the treatment of neuropathic pain in diabetic peripheral neuropathy (333369-NPP-2002),
Role: Investigator,
Johnson & Johnson,
(02/2008 - 02/2009)
Status: Completed
A randomized, double-blind, placebo-controlled, parallel-group with a crossover confirmation period study of RWJ-333369 for the treatment of postherpetic neuralgia (333369-NNP-2001),
Role: Investigator,
Johnson & Johnson,
(01/2008 - 01/2009)
Status: Completed
Multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of lenalidomide in the treatment of complex regional pain syndrome type I,
Role: Investigator,
Celgene, Inc.,
(01/2008 - 01/2009)
Status: Completed
A randomized double-blind, placebo-controlled, two-way cross over study of analgesic efficacy of bupivacaine transdermal therapeutic system in patients with post-herpetic neuralgia,
Role: Investigator,
Durect Corporation,
(09/2007 - 09/2008)
Status: Completed
An open label, long term treatment evaluation of the safety of BEMATM fentanyl use for breakthrough pain in cancer subjects on chronic opioid therapy,
Role: Investigator,
BioDelivery Sciences International, Inc.,
(09/2007 - 09/2008)
Status: Completed
A double-blind, randomized, placebo-controlled study of modafinil and morphine or oxycodone in patients with excessive daytime sleepiness due to opioid therapy,
Role: Investigator,
Medgenex, Inc.,
(03/2007 - 03/2008)
Status: Completed
An open-label, long-term safety study to evaluate the safety of the ZR-02-01 Matrix Transdermal Fentanyl patch for the treatment of moderate to severe non-malignant chronic pain.,
Role: Investigator,
ZARS, Inc.,
(07/2006 - 07/2007)
Status: Completed
An open-label, long -term safety study to evaluate the safety of the ZR-02-01 Matrix Transdermal Fentanyl patch for the treatment of moderate to severe cancer pain.,
Role: Investigator,
ZARS, Inc.,
(07/2005 - 07/2006)
Status: Completed
A randomized, double-blinded, placebo-controlled, multicenter phase IIb study to evaluate the efficacy and safety of Multiple Alvimopan dosage regimens for the treatment of Opioid-induced bowel dysfunction in subjects with chronic pain of non-malignant origin,
Role: Investigator,
GlaxoSmithKline,
(08/2004 - 08/2005)
Status: Completed
A comparison of the efficacy and safety of topomax tablets versus placebo for the prophylaxis of migraine protocol CAPSS-155 (Protocol issue date: 04 August 2000, Document No: EDMS-USRA-5530809:2.0),
Role: Investigator,
Ortho-McNeil Pharmaceutical,
(09/2001 - 09/2002)
Status: Completed
The safety and efficacy of electrotransport E-TRANS (fentanyl HCI) 40 mcg for the treatment of post operative pain: a double blind, multicenter, placebo-controlled trial incorporating JCAHO Pain Management Standards, edition date: June 20, 2001.,
Role: Investigator,
ALZA Corporation,
(09/2001 - 09/2002)
Status: Completed
A randomized, double-blind, placebo-controlled comparison of the analgesic activity of valdecoxib (SC-65872) 40 mg bid as add-on therapy to opoid medication in patients with chronic cancer pain,
Role: Investigator,
Searle,
(07/2001 - 07/2002)
Status: Completed
Clinical protocol for a multicenter, double-blind, randomized study of the efficacy and safety of a single dose of IV parecoxib followed by up to seven days of oral valdecoxib for the pain following laparascopic cholecystectomy, parecoxib IND# 52613, valdecoxib IND #52153,
Role: Investigator,
Searle,
(02/2001 - 02/2002)
Status: Completed
A randomized, double-blind, parallel-design, placebo and active controlled, multicenter, ascending dose-ranging study of the safety and efficacy of single doses of Org 41793 in the treatment of post-operative pain in ASA Class I and II surgical inpatients. (Protocol No. 139-002, dated 08 August 2000),
Role: Investigator,
Organon USA Inc.,
(09/2000 - 09/2001)
Status: Completed
Clinical Protocol for The Safety and Efficacy o f Electrotransport (E-TRANS) Fentanyl Compared to IV PCA Morphine for the Treatment of Post-Operative Pain, IND # 41,574 (Version August 2, 2000),
Role: Investigator,
ALZA Corporation,
(08/2000 - 08/2001)
Status: Completed
An open, randomized, 2-way crossover study comparing the treatment chronic non-malignant pain with duragesic and oxycontin,
Role: Investigator,
Janssen Pharmaceutical Products, L.P.,
(02/2000 - 02/2001)
Status: Completed
A phase III, multi-center, double-blind, randomized, placebo-controlled study of the reversal of opioid-induced gastrointestinal dysfunction in subjects receiving chronic opioid therapy for pain or opioid addiction. [Protocol 13C304 - Version Date as of Amendment 1, April 17, 2001],
Role: Investigator,
Adolor Corporation,
Status: Completed
A multicenter, randomized, double-blind, placebo-controlled,parallel group study to assess the safety and efficacy of GW406381 25 mg and 50 mg, administered once daily for 21 days to subjects with postherpetic neuralgia,
Role: Investigator,
GlaxoSmithKline,
Status: Completed
Internal
A phase II, multi-center, randomized, double-blind, placebo-controlled study of CJC-1008, a long acting, parenteral, opioid analgesic, in the treatment of surgical pain following total knee arthroplasty, IND #60,935. Protocol version: 06/22/01,
Role: Investigator,
LLU Dept. of Anesthesiology,
(01/2002 - 01/2003)
Status: Completed